Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings targets. The parties expect the deal to close in July or early August...